RNA and CAR-T biotech Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
? ?
00:22
Apr 30
Kim Hyeong-cheol CEO, Kim Hyung-chul Research Institute 815 Money Talk (815머니톡)
ST Pharm RNA CDMO demand
ST Pharm is a key beneficiary in RNA and CDMO, and the speaker sees RNA and CAR-T as important bio themes, supported by Lilly's shopping list for CAR-T companies and aging demographics.
RNA and CAR-T biotech
MED

About RNA and CAR-T biotech Investor Commentary

Across the available history and selected sources, Buzzberg tracks RNA and CAR-T biotech across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Kim Hyeong-cheol.